Related by context. All words. (Click for frequent words.) 78 ocular adverse 76 laboratory abnormalities 75 hematologic adverse 75 events AEs 75 TEAEs 74 Treatment emergent adverse 73 discontinuations due 73 Adverse events 72 nasopharyngitis 70 adverse reactions observed 70 hematological adverse 70 adverse reactions incidence 70 AEs 69 events TEAEs 69 headache nasopharyngitis 69 incidence ≥ 68 peripheral edema 67 oxycodone CR 67 TYSABRI treated 67 thromboembolic events 67 pyrexia mucositis sepsis febrile 66 febrile neutropenia 66 leukopenia 66 diarrhea nausea fatigue 66 severe hypoglycemic 66 thromboembolic 66 events SAEs 66 infusion reactions 66 treatment emergent AEs 65 oral olanzapine 65 lopinavir r arm 65 neutropenia dehydration dyspnea 65 adverse reactions occurring 65 peripheral sensory neuropathy 65 hypoglycemic events 65 arterial thromboembolic events 65 ALT flares 65 linaclotide treated 65 SAEs 65 composite endpoint 65 arthralgia 64 discontinuations 64 mg BID 64 leucopenia 64 hypokalemia 64 hematologic toxicity 64 severe exacerbations 63 nonfatal MI 63 diarrhea nausea vomiting 63 mcg QD 63 pyrexia 63 Serious ocular 63 REYATAZ r arm 63 Hypersensitivity reactions 63 Erythropoietic therapies may 63 myelosuppression 63 extrapyramidal symptoms 63 lymphopenia 63 syncopal 63 desvenlafaxine succinate 63 neutropenia thrombocytopenia 63 patients receiving ERBITUX 63 adverse reactions ≥ 63 constipation nausea 62 solifenacin 62 QTc prolongation 62 DLTs 62 mcg BID 62 infection nasopharyngitis 62 Peripheral edema 62 unresectable HCC 62 cerebrovascular events 62 hallucinations dyskinesia 62 hypercalcemia 62 paresthesias 62 hepatic adverse 62 severe hypersensitivity reactions 62 superficial edema 61 nasopharyngitis headache 61 asthenia 61 tolvaptan 61 gout flare 61 neutropaenia 61 evaluable 61 adjunctive placebo 61 APTIVUS r 61 adverse reactions irrespective 61 ARCALYST ® 61 epistaxis 61 definite stent thrombosis 61 Keppra R 61 ACTEMRA TM 61 non selective NSAIDs 61 pruritis 61 fatigue asthenia 61 nausea somnolence 61 non hematological toxicities 61 thrombocytopenia 61 hypomagnesemia 61 dose limiting toxicities 61 RLAI 61 transaminase elevations 61 teriflunomide 61 tapentadol ER 61 generalized edema 61 neutropenia 61 somnolence dizziness 61 certolizumab 61 dapagliflozin plus 60 stomatitis 60 FluCAM arm 60 PREZISTA r 60 gastrointestinal toxicities 60 ARCOXIA 60 Febrile neutropenia 60 acneform rash 60 headache nausea diarrhea 60 hypersensitivity reactions 60 COPD exacerbation 60 ALVESCO 60 achieved statistical significance 60 mg dose 60 lacosamide 60 Adverse reactions 60 somnolence sedation 60 extrapyramidal disorder 60 FOLPI 60 nonfatal stroke 60 chills fever headache 60 EXJADE 60 #mg BID [003] 60 ipsilateral stroke 60 myocardial infarction stroke 60 comparator arm 60 reinfarction 60 gout flares 60 endophthalmitis 60 insomnia somnolence 60 mg TID 60 headache abdominal pain 60 lipid parameters 59 severe neutropenia 59 hypophosphatemia 59 dizziness somnolence 59 prolonged QT interval 59 ATACAND 59 mucositis 59 receiving ISENTRESS 59 thrombotic events 59 secondary efficacy endpoints 59 elevated ALT 59 adjunctive ABILIFY 59 receiving XGEVA 59 virologic breakthrough 59 PREZISTA r arm 59 receiving INTRON 59 virologic failure 59 intraocular inflammation 59 neutropenia febrile neutropenia 59 generalized seizures 59 hemorrhagic complications 59 hematological toxicities 59 periprocedural 59 insulin detemir 59 experienced hypomagnesemia 59 MACCE 59 dizziness headache 59 intravitreal injections 59 ECG abnormalities 59 chlorambucil 59 â ‰ ¥ 59 Neutropenia 59 intravenous bisphosphonates 59 ARB telmisartan 59 limiting toxicity 59 placebo 59 CIMZIA TM 59 myalgia 59 QTc 59 LEXIVA r 59 patients evaluable 59 dyspnea 59 PGTC seizures 59 thromboembolism 59 #mg/day [001] 58 thrombocytopenia neutropenia 58 pharyngolaryngeal pain 58 pruritus itching 58 pericardial effusion 58 mcg albinterferon alfa 2b 58 ACTEMRA 58 Infusion Reactions Severe 58 salmeterol HFA MDI 58 RLS symptoms 58 zolmitriptan 58 achieved ACR# 58 Major Adverse Cardiac 58 posaconazole 58 nonfatal cardiovascular 58 dizziness nausea diarrhea 58 peginterferon alfa 2b 58 pruritus 58 ABC/3TC 58 GSK# [001] 58 serious Interstitial Lung 58 gastrointestinal perforation 58 recurrent venous thromboembolism 58 liver transaminases 58 lumiracoxib 58 mycophenolate mofetil 58 primidone 58 TDF FTC 58 Treatment discontinuations due 58 PREZISTA rtv 58 x ULN 58 nadroparin 58 mcg Albuferon 58 serologically active patients 58 myopathy rhabdomyolysis 58 tolterodine ER 58 baseline HbA1c 58 macrovascular events 58 recurrent VTE 58 ≥ 58 venous thromboembolic events 58 beclomethasone dipropionate 58 Lactic acidosis 58 hyperkalemia 58 headache nausea fatigue 58 cardiovascular thrombotic 58 plus methotrexate 58 events MACE 58 recurrent coronary 58 Baseline characteristics 58 quetiapine 58 angioneurotic edema 58 anaphylactoid reactions 58 VIIBRYD 58 Discontinuations 58 nausea constipation 58 colorectal adenoma 58 dizziness headache nausea 58 octreotide LAR 58 GERD symptom 58 Exacerbations 58 Primary endpoints 58 DOXIL 58 gastrointestinal toxicity 58 concomitant medications 58 Toxicities 58 β blockers 58 apnea hypopnea 58 FOLFIRI 58 symptomatic VTE 58 concomitant AEDs 58 ximelagatran 58 GOUT 58 certolizumab pegol 58 INVEGA ® 58 Q2W 58 placebo p 57 Secondary endpoints 57 Lamictal XR 57 cholecystitis 57 anticholinergics 57 rizatriptan 57 Stent thrombosis 57 generalized tonic clonic seizures 57 myalgia arthralgia 57 Serious adverse reactions 57 mg ustekinumab 57 zonisamide SR 57 mg QD 57 LAMICTAL 57 4mg/kg 57 #mg BID [001] 57 glycated hemoglobin levels 57 Discontinuations due 57 TMC# r 57 lispro 57 lenalidomide dexamethasone 57 jaw ONJ 57 tapentadol IR 57 elevated liver enzymes 57 Hypocalcemia 57 anemia neutropenia 57 glimepiride 57 ARIXTRA 57 adverse reactions 57 HBeAg seroconversion 57 alpha interferons 57 unstable angina pectoris 57 arterial thromboembolic 57 secondary endpoint 57 HBeAg negative patients 57 acute coronary syndromes ACS 57 SSRI SNRI 57 valacyclovir 57 oxycodone IR 57 nausea diarrhea 57 arthralgias 57 bosentan 57 hemoptysis 57 Secondary endpoints included 57 hypotension 57 tiotropium 57 abdominal pain headache 57 idraparinux 57 receiving VELCADE 57 GERD symptoms 57 PRADAXA 57 prespecified 57 Xeloda monotherapy 57 confirmed thrombotic cardiovascular 57 melphalan prednisone 57 ischemic cardiovascular 57 leukotriene receptor antagonists 57 hepatotoxicity 57 mg kg dose 57 hematologic toxicities 57 highly emetogenic 57 placebo controlled clinical trials 57 placebo controlled studies 57 venlafaxine ER 57 Renal impairment 57 #mg doses [002] 57 recurrent ischemia 57 hypocalcemia 57 hematological toxicity 57 NPH insulin 57 angiotensin converting enzyme inhibitors 57 somnolence 57 akathisia 57 MADRS score 57 EFFEXOR XR 57 somnolence headache 57 Disease ILD 57 lamotrigine 57 Flu Cy 57 NATRECOR ® 57 evaluable subjects 57 alanine aminotransferase 57 mcg kg REBETOL 57 mcg doses 56 ecchymosis 56 rFVIIa 56 INFERGEN 56 postoperative AF 56 PASI scores 56 IBS C 56 recurrent genital herpes 56 triamcinolone 56 Myelosuppression 56 hepatic failure 56 Serious AEs 56 CIMZIA TM certolizumab pegol 56 lipid lowering agents 56 tumor lysis syndrome 56 INTRON 56 pheochromocytoma 56 symptom exacerbation 56 NATRECOR R 56 angioedema 56 orthostatic hypotension 56 tirofiban 56 renal impairment 56 pegylated interferon alfa 2b 56 TMP SMX 56 haematologic 56 aminotransferase elevations greater 56 corticosteroid therapy 56 VaD 56 receiving VICTRELIS 56 fulminant hepatitis 56 impaired renal 56 lopinavir r 56 8mg/kg 56 nonsignificant 56 Serious Adverse Events 56 thromboembolic complications 56 ertapenem 56 diarrhea headache nausea 56 spinal cord compression 56 serum urate 56 oral levofloxacin 56 cerebrovascular adverse 56 headache nausea 56 tamsulosin 56 NNT = 56 salmeterol fluticasone 56 telcagepant 56 cytopenias 56 nausea dizziness vomiting 56 AA Amyloidosis 56 benazepril 56 prednisone prednisolone 56 abdominal pain flatulence 56 exacerbations 56 mucosal inflammation 56 Kaplan Meier estimates 56 ACR# response 56 placebo p = 56 Hypotension 56 PRADAXA #mg 56 symptomatic hypoglycemia 56 plus gemcitabine 56 analgesic medications 56 placebo fluoxetine 56 gastrointestinal adverse reactions 56 DETROL LA 56 Torsades de Pointes 56 abacavir lamivudine 56 6R BH4 56 morphometric vertebral fractures 56 oral allopurinol 56 FOLFOX4 56 nausea fatigue 56 delayed CINV 56 ribavirin therapy 56 dermatologic reactions 56 placebo dexamethasone 56 statistically significant p 56 REYATAZ ritonavir 56 timepoint 56 nonfatal myocardial infarction 56 gemifloxacin 56 CIMZIA ™ 56 renal toxicity 56 myocardial infarctions 56 heparin induced thrombocytopenia 56 toxicities 56 moderate renal impairment 56 dyspareunia 56 recurrent glioblastoma multiforme 56 dose regimens 56 proliferative diabetic retinopathy 56 spontaneous bowel movements 56 nonaspirin 56 incontinence episodes 56 Index CDAI 56 vasomotor symptoms 56 FFNS 56 peginterferon alfa 2a 56 cardiovascular ischemic 56 severe hypoglycemia 56 headache somnolence 56 myocardial infarction MI 56 nephrotoxicity 56 virologic response 56 ketoconazole 56 nonrandomized 56 receiving golimumab 56 headache diarrhea nausea 56 LVEF 56 Angioedema 56 timepoints 56 Psoriasis Area 56 MAXALT 56 rosuvastatin #mg 56 torsades de pointes 56 transaminases 56 tolerability profiles 56 #mg/day [002] 56 dosage regimens 56 anterior uveitis 56 doxazosin 56 arterial thrombotic 55 asthenia pain 55 limiting toxicity DLT 55 Crohn Disease Activity 55 conjunctival hyperemia 55 biologic DMARD 55 nadolol 55 angina pectoris 55 Perforomist Inhalation Solution 55 relapsed MM 55 del 5q MDS 55 advanced adenomas 55 microvascular complications 55 LEXIVA 55 HBeAg positive patients 55 venlafaxine Effexor 55 primary generalized tonic 55 binary restenosis 55 nonhematologic adverse reactions 55 NOLVADEX 55 HMG CoA reductase inhibitors 55 postoperative nausea 55 elotuzumab 55 intracranial hemorrhage ICH 55 prednisone prednisolone plus 55 musculoskeletal pain 55 somnolence fatigue 55 hypoglycemia 55 nonvertebral fractures 55 failure ADHF 55 RAPTIVA 55 typical antipsychotics 55 5-FU/LV 55 urate lowering therapy 55 hepatic dysfunction 55 #mg/m# [001] 55 ACR# ACR# 55 endometrial hyperplasia 55 systemic embolism 55 TNF antagonist 55 cardiovascular hospitalization 55 recurrent DVT 55 antiepileptics 55 oral rivaroxaban 55 AGILECT R 55 recurrent ischemic 55 telaprevir dosing 55 antihypertensive medications 55 adalimumab 55 MCyR 55 ULORIC 55 CANCIDAS 55 headache arthralgia 55 COPD exacerbations 55 ruboxistaurin 55 ALT elevations 55 tipranavir r 55 BENICAR HCT 55 ug dose 55 headache dizziness 55 Thrombolysis 55 diarrhea nausea 55 oral FTY# 55 reactogenicity 55 QTcF 55 ibandronate 55 BARACLUDE r 55 unfractionated heparin UFH 55 CR nPR 55 VAPRISOL 55 antithrombotics 55 H2 receptor antagonists 55 FOLFOX 55 DU #b 55 bezafibrate 55 levetiracetam 55 radiation dermatitis 55 COZAAR 55 p = NS 55 Discontinuation 55 ADHF 55 PREMPRO 55 QT prolongation 55 neurologic symptoms 55 ziprasidone 55 saline placebo 55 infliximab monotherapy 55 elevated creatinine 55 AGILECT ® 55 oral diclofenac 55 YMRS 55 hypersensitivity reaction 55 NSTEMI 55 acarbose 55 nausea vomiting headache 55 virological failure 55 1mg dose 55 abdominal pain abdominal discomfort 55 locoregional recurrence 55 thrombophlebitis 55 DAS# scores 55 #mg dose [003] 55 HbA1c levels 55 anemia constipation diarrhea 55 cabazitaxel 55 sensory neuropathy 55 nondiabetic patients 55 placebo controlled clinical 55 neutropenia anemia 55 Elitek 55 ischemic cerebrovascular 55 Adalimumab 55 CCyR 55 stent thromboses 55 active comparator 55 pyridostigmine 55 NSAID ibuprofen 55 UACR 55 hypoglycemic episodes 55 hypoglycaemia 55 photosensitivity rash 55 R adefovir dipivoxil 55 anaphylactoid 55 SVR# 55 nonvertebral fracture 55 headache flushing 55 Syndrome RLS 55 secondary efficacy endpoint 55 carotid stenosis 55 hepatic impairment 55 nonresponders 55 canakinumab 55 antiepileptic drugs AEDs 55 fatigue abdominal pain 55 mg/m2 dose 55 divalproex 55 vWD 55 sulfasalazine 55 mcg mL 55 coinfected patients 55 bronchospasm 55 hypoglycaemic episodes 54 Pegasys plus Copegus 54 renal insufficiency 54 induce orthostatic hypotension 54 HCV SPRINT 54 oral vancomycin 54 emotional lability 54 aspartate aminotransferase AST 54 nighttime awakenings 54 inflammatory lesions 54 #mg BID [002] 54 lactic acidosis 54 cardiac toxicity 54 ACE inhibitor ramipril 54 Tolerability 54 HbA 1c levels 54 oral prednisolone 54 aldosterone antagonist 54 acute coronary 54 venlafaxine XR 54 secondary endpoints 54 mcg linaclotide 54 CorVue ™ 54 malignancy HCM 54 nocturnal awakenings 54 tenofovir emtricitabine 54 prespecified secondary 54 P = .# 54 nausea headache 54 vitreous floaters 54 paroxetine Paxil 54 ipsilateral breast 54 fatal anaphylactic 54 metformin sulfonylurea 54 aspirin clopidogrel 54 infusional 54 VT VF 54 anakinra 54 hematologic adverse reactions 54 Severe cutaneous 54 URTI 54 aminotransferases 54 headache myalgia 54 refractory gout 54 ischemic cardiomyopathy 54 Telithromycin 54 cough wheezing 54 asthma exacerbation 54 HIV HCV coinfected 54 double blinded placebo 54 bolus dose 54 primary hypercholesterolemia 54 doxorubicin cyclophosphamide 54 pruritus rash 54 paresthesia 54 olanzapine LAI 54 CrCl 54 XIENCE V PROMUS Stent 54 vertebral fractures 54 INVEGA 54 Adverse Events 54 risperidone Risperdal 54 pioglitazone 54 LATUDA 54 Thrombocytopenia 54 Peg IFN 54 MoxDuo TM IR 54 rhinorrhea 54 diarrhea nausea abdominal pain 54 HAMD 54 mg/# h 54 macroalbuminuria 54 RAPAFLO R 54 pancytopenia 54 splenectomized patients 54 HAM D# 54 ZYVOX 54 stable angina 54 adriamycin 54 anaphylactic reactions bronchospasm 54 fluticasone salmeterol 54 ONGLYZA 54 PEGINTRON TM 54 moderate ulcerative colitis 54 KRAS mutations occur 54 asthenia fatigue 54 clinically meaningful reductions 54 cytogenetic response 54 Thrombotic events 54 mCRC acneform rash 54 hepatic enzymes 54 homozygous familial hypercholesterolemia 54 symptomatic pulmonary embolism 54 dysmenorrhoea 54 erythema redness 54 ICD shocks 54 hyperbilirubinemia 54 nausea diarrhea constipation 54 alicaforsen enema 54 abdominal distension 54 demonstrated statistically significant 54 fingolimod 54 ‰ ¥ 54 Secondary endpoints include 54 aspartate aminotransferase 54 angiotensin II receptor blockers 54 mild renal impairment 54 neuropsychiatric adverse 54 frequent awakenings 54 oral antidiabetic medication 54 ACTOplus met 54 serum phosphorus 54 R# #mg BID 54 diarrhea nausea stomatitis 54 macrovascular 54 hypersomnia 54 asthma exacerbations 54 voriconazole 54 EURIDIS 54 Navelbine 54 mitoxantrone 54 mucocutaneous reactions 54 microbiological eradication 54 Vaprisol 54 resuscitated cardiac arrest 54 FluCAM 54 pooled comparator 54 HAM D# scores 54 tricyclic antidepressants 54 Folfox 54 Liver toxicity 54 serum phosphorous 54 interferon alfa 54 nausea vomiting headache dizziness 54 ZIAGEN 54 endoscopic remission 54 esophagitis 54 μg kg 54 antiemetics 54 somnolence sleepiness 54 LPV r 54 budesonide pMDI 54 Events MACE 54 aripiprazole 54 nonfatal myocardial infarction MI 54 nontraumatic 54 gastrointestinal GI 54 anaphylactic reactions 54 Brief Psychiatric 54 Hematologic 54 FOSRENOL ® 54 vasogenic edema 54 Perforomist TM Inhalation Solution 54 subclinical hypothyroidism 54 Pegasys ® 54 Pioglitazone 54 PREZISTA ritonavir 54 runny nose nasal congestion 54 JANUVIA 54 flutamide 54 ADCS CGIC 54 Montgomery Asberg Depression 54 VFEND 54 dyslipidaemia 54 paliperidone ER 54 tacrolimus ointment 54 headache nausea dizziness 54 FOLPI regimen 54 constipation somnolence nausea 54 Lantus R 54 MIRAPEX ER 54 OADs 54 coronary stenoses 54 myalgias 54 clinically meaningful differences 54 ACR# responses 54 IOP lowering 54 primary efficacy endpoint 54 thrombocytopenia anemia 54 anticoagulant warfarin 54 headache tiredness dizziness 54 + PH# 54 INC# 54 left ventricular dysfunction 54 aseptic meningitis 54 urinary N telopeptide 54 necrotizing pancreatitis 54 CVD mortality 54 CIMZIA 54 torsade de pointes 54 gadobutrol 54 apremilast 54 tranylcypromine 54 nicardipine 54 moderately emetogenic 54 MYCAMINE 54 pulmonary exacerbation 54 invasive candidiasis 54 antiarrhythmic drug 53 eplerenone 53 intracerebral hemorrhage 53 Dose limiting toxicities 53 HbA 1c 53 fluconazole 53 Doxil ® 53 EEG abnormalities 53 Severe infusion 53 Hepatotoxicity 53 CIMZIA R 53 hemorrhagic strokes 53 VTE 53 serum potassium 53 non metastatic osteosarcoma 53 neovascular glaucoma 53 anemia leukopenia 53 #.#g/day 53 mg doses 53 dose cohorts 53 Aptivus ® 53 BROVANA 53 #.#mg/dL 53 mg eq 53 oxcarbazepine 53 KIF6 carriers 53 aldosterone antagonists 53 serious cardiovascular thrombotic 53 apnea hypopnea index 53 ARCALYST 53 histologic subtype 53 anemia nausea 53 diabetic neuropathic pain 53 nausea vomiting fatigue 53 rimonabant #mg 53 Zometa hazard 53 plus dexamethasone 53 irbesartan 53 PEG Intron 53 TIMI 53 ribavirin RBV 53 Lipitor #mg 53 montelukast 53 INCB# [003] 53 daunorubicin 53 symptomatic hypotension 53 placebo controlled 53 confidence interval CI 53 ZOMIG Nasal Spray 53 NIH CPSI 53 β blocker 53 hyperphenylalaninemia HPA due 53 SBMs 53 postoperative complication 53 imipenem 53 candidemia 53 ABILIFY 53 MIRAPEX 53 HF hospitalization 53 neutropenic fever 53 thyrotoxicosis 53 ropivacaine 53 ORENCIA 53 viral kinetic 53 XIENCE V demonstrated 53 cilostazol 53 Hyponatremia 53 ACEIs 53 severe hepatomegaly 53 dysuria 53 retinal vein occlusion 53 ARICEPT 53 IIIa inhibitors 53 bleeding ulceration 53 vaccinees 53 mg XP# 53 diarrhea dyspepsia 53 divalproex sodium 53 baseline A1C 53 FROVA 53 milrinone 53 mg BID dose 53 prospectively defined 53 peg IFN 53 depressive symptom 53 Keppra ® 53 coadministration 53 neurologic complications 53 relapsing remitting 53 Rituxan infusion 53 plus OBT 53 exploratory endpoints 53 abciximab 53 AVANDIA 53 pramipexole 53 symptomatic hyponatremia 53 Kidney toxicity nephrotoxicity 53 Neuroleptic Malignant Syndrome NMS 53 telbivudine 53 sUA 53 generalized epilepsy 53 thromboprophylaxis 53 decitabine 53 INVANZ 53 titrated glipizide 53 MMX mesalamine 53 Reversible Posterior Leukoencephalopathy Syndrome 53 levofloxacin 53 ventricular fibrillation VF 53 evaluable patients 53 hemorrhagic cystitis 53 SREs 53 Vertebral fractures 53 interferon alfa 2b 53 chills fatigue 53 ritonavir boosted 53 Herpes infections 53 sumatriptan naproxen sodium 53 salmeterol fluticasone propionate 53 AVELOX 53 mcg kg 53 phenytoin 53 corrected QT interval 53 enoxaparin 53 unfractionated heparin 53 AIR CF1 53 EVIZON 53 olanzapine 53 fatal myocardial infarction 53 acromegalic patients 53 included exfoliative dermatitis 53 acute gout flares 53 NEVO ™ 53 clinically meaningful improvements 53 triptan 53 NLX P# 53 intermittent dosing 53 Fludara 53 Fibrates 53 BYSTOLIC 53 achieved PASI 53 subtrochanteric 53 hypercholesterolaemia 53 accompanying hypocalcemia 53 mg q#h 53 vandetanib 53 symptomatic BPH 53 stroke transient ischemic 53 glulisine 53 plus GP IIb 53 administered erythropoiesis stimulating 53 inhaled budesonide 53 MACUGEN 53 dysgeusia 53 events thrombocytopenia neutropenia 53 anemia hemoglobin 53 Januvia ® 53 μg dose 53 ritonavir boosted atazanavir 53 etanercept 53 dermatologic toxicities 53 Severe hypersensitivity reactions 53 retinal thickness 53 diarrhea flatulence 53 dizziness constipation 53 sustained ventricular tachycardia 53 serotonergic drugs 53 HBeAg positive 53 thiazolidinedione TZD 53 proximal DVT 53 atypical antipsychotic medications 53 OAB symptoms 53 Engerix B 53 quetiapine XR 53 Lupuzor ™ 53 dyskinesia PD LID 53 TAXUS p value 53 valsartan amlodipine 53 NAbs 53 Negative Syndrome 53 neuropsychiatric symptoms 53 eszopiclone 53 SJIA 53 IIIa inhibitor 53 febuxostat 53 creatinine clearance 53 plaque psoriasis 53 visilizumab 53 palonosetron 53 acutely decompensated congestive heart 53 DVT PE 53 #.#/#.# mmHg [001] 53 mesalamine 53 alanine aminotransferase ALT